Jco precision oncology.

PURPOSE The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population ...The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ... DOI: 10.1200/PO.19.00388 JCO Precision Oncology no. 4 (2020) 882-897. Published online July 28, 2020. PMID: 35050761. Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial Clare Gilson, MRCP, MD 1. x. Clare Gilson. Search for …WebDOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017Web

DOI: 10.1200/PO.21.00152 JCO Precision Oncology no. 5 (2021) 1639-1649. Published online October 22, 2021. Published online October 22, 2021. PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsDOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017Web

PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the …DOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019

DOI: 10.1200/PO.20.00257 JCO Precision Oncology no. 4 (2020) 1393-1402. Published online November 16, 2020. Published online November 16, 2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesDOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...PURPOSE Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low HER2-expressing breast cancers benefit from trastuzumab-deruxtecan. Little is known about HER2 transcriptomic (mRNA) expression, and comparisons between ...DOI: 10.1200/PO.18.00226 JCO Precision Oncology - published online January 22, 2019

Jul 28, 2020 · PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...

JCO precision oncology Machine Name 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.

DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019DOI: 10.1200/PO.22.00197 JCO Precision Oncology no. 6 (2022) e2200197. Published online September 15, 2022. PMID: 36108259. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy ...The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ...Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. ... JCO Precis Oncol. 2019 Dec …DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...

DOI: 10.1200/PO.18.00356 JCO Precision Oncology - published online May 16, 2019 Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model Nathan A. Pennell, MD, PhD 1. x. Nathan A. Pennell. Search for articles …JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not accepted for publication for reasons of priority. Such papers may be more appropriate for an oncology specialty journal such as JCO PO. In that regard, JCO PO 's new program will ...Feb 16, 2022 · The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ... DOI: 10.1200/PO.21.00267 JCO Precision Oncology no. 6 (2022) e2100267. Published online February 2, 2022. PMID: 35108036. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers Benjamin Garmezy, MD 1. x ...JCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...

DOI: 10.1200/PO.18.00037 JCO Precision Oncology - published online July 23, 2018Web

PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ... 詳細. タイトル. JCO precision oncology. JCO precision oncology. ... American Society of Clinical Oncology, publisher. ... Began with February 22, 2017. Began with ...Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ... Mar 9, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines 15 Sept 2023 ... 5. Johnson A , Khotskaya YB , Brusco L , et al. Clinical use of precision oncology decision support. JCO Precis Oncol. 2017. doi:10.1200 ...Oct 20, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche

DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...

6 Oct 2022 ... Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol 2017, PO.

Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.DOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ...JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebDOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. DOI: 10.1200/PO.21.00101 JCO Precision Oncology no. 5 (2021) 1166-1177. Published online July 21, 2021. Published online July 21, 2021. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesAn Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022.

Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ... DOI: 10.1200/PO.19.00333 JCO Precision Oncology no. 4 (2020) 411-425. Published online April 23, 2020. PMID: 35050738. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review Jing Zhao, MD 1. x. Jing Zhao. Search for articles by this author. and Yang ...WebDOI: 10.1200/PO.20.00280 JCO Precision Oncology no. 5 (2021) 215-226. Published online January 19, 2021. PMID: 34994597. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) ...WebDOI: 10.1200/PO.19.00292 JCO Precision Oncology no. 4 (2020) 244-257. Published online March 27, 2020. PMID: 32923909. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy Shunying Li, PhD 1, 2. x. Shunying Li. Search for articles by this author ...Instagram:https://instagram. top schwab mutual fundshow to invest in chatgpthermes stock priceaustralian lithium stocks Alberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go. solid state battery makerspsny stock forecast Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with … alignment health plan.com DOI: 10.1200/PO.20.00383 JCO Precision Oncology no. 5 (2021) 756-766. Published online May 3, 2021. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors Yuki Takeyasu, MD 1, 2. x. Yuki Takeyasu. Search for articles by this author; Hitomi S. Okuma, MD, PhD 1, 3. x. Hitomi S. Okuma ...DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...